Two-peptide research blend
A research-use co-formulation of BPC-157 and TB-500 at matched strengths in a single lyophilised vial. Supplied as a 10 mg / 10 mg vial, or as a pre-filled research pen in 10 mg / 10 mg, 20 mg / 20 mg and 30 mg / 30 mg.
| Compound | Wolverine Stack (BPC-157 / TB-500) |
| Research category | Regenerative Research |
| Composition | BPC-157 and TB-500, co-formulated at matched strengths |
| Available sizes | Vial: 10 mg / 10 mg · Pen: 10 mg / 10 mg, 20 mg / 20 mg, 30 mg / 30 mg |
| Pricing | Vial £50 · Pen £80 / £120 / £155. Prices exclude postage. |
| Format | Lyophilised powder in sealed vial |
| Purity | >99% by HPLC per component (Janoshik Analytical, batch-verified) |
| Intended use | In-vitro laboratory research only. Not for human consumption. |
Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.
| Compound class | Two-peptide research blend (BPC-157 pentadecapeptide + TB-500 thymosin β4 fragment) |
| Molecular formula | Blend |
| Molecular weight | Blend (BPC-157 1419.5 g/mol; TB-500 1889.1 g/mol) |
| CAS Registry Number | N/A (blend). Components: 137525-51-0 (BPC-157), 77591-33-4 (TB-500) |
| Amino acid sequence | Blend - refer to constituent peptide data. |
| Receptor / mechanism | Refer to constituent peptide profiles. |
| Reported half-life | Variable per component. BPC-157 approximately 4 hours reconstituted; TB-500 extended via actin binding. |
| Solubility | Lyophilised powder reconstitutes in bacteriostatic water for laboratory use. |
| Storage (lyophilised) | Stable at 2–8 °C lyophilised for 18+ months. |
| Storage (reconstituted) | Reconstituted: store at 2–8 °C, use within 14 days. |
| Clinical / regulatory status | Research blend. Neither component is an approved medicine in the UK. |
The Wolverine Stack co-formulates the two compounds most frequently paired in the preclinical tissue-repair literature. BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein, characterised in the Sikiric group's tendon and gut-mucosal models. TB-500 is a synthetic fragment of Thymosin Beta-4, characterised for its role in actin sequestration and cellular migration. Supplying both in one vial at matched strengths removes the need to reconstitute and handle two separate preparations. Supplied for in-vitro research use only.
The above describes how these compounds are characterised in the published peer-reviewed literature. It is not a claim about effects in humans.
The Wolverine Stack is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.
Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration. Note that a 10 mg / 10 mg vial reconstituted in 2 ml yields 5 mg/ml of each component.
| State | Temperature | Shelf life |
|---|---|---|
| Lyophilised | 2–8 °C or −20 °C | Up to 24 months |
| Reconstituted | 2–8 °C | 4–6 weeks typical |
Every batch of the Wolverine Stack we supply is independently HPLC-verified by Janoshik Analytical, with each component tested separately before blending. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.
Researchers working with the Wolverine Stack often work alongside the following compounds in the preclinical literature:
Chemical and reference data for the Wolverine Stack is drawn from public chemical registries (CAS, PubChem) and the independent peer-reviewed literature. All sources are third-party and independently verifiable; Lab77 Peptides is not affiliated with the cited publications or databases.